Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
injection
|
| gptkbp:alsoKnownAs |
gptkb:Ervebo
gptkb:rVSVΔG-ZEBOV-GP |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:clinicalTrialPhase |
gptkb:Guinea_Ebola_outbreak_2015
|
| gptkbp:contains |
gptkb:recombinant_vesicular_stomatitis_virus
gptkb:Zaire_ebolavirus_glycoprotein_gene |
| gptkbp:developedBy |
gptkb:Merck
|
| gptkbp:effect |
high
|
| gptkbp:form |
single dose
|
| https://www.w3.org/2000/01/rdf-schema#label |
vaccine (rVSV-ZEBOV)
|
| gptkbp:indication |
adults 18 years and older
|
| gptkbp:notRecommendedFor |
children under 18
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:sideEffect |
fever
headache muscle pain injection site pain |
| gptkbp:storage |
-80°C to -60°C
|
| gptkbp:target |
gptkb:Zaire_ebolavirus
|
| gptkbp:type |
live attenuated vaccine
|
| gptkbp:usedFor |
prevention of Ebola virus disease
|
| gptkbp:WHOPrequalified |
2019
|
| gptkbp:bfsParent |
gptkb:Ebola_virus_disease
|
| gptkbp:bfsLayer |
6
|